ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
As immuno-oncology heads into 2019, one thing is clear: It’s good to be Merck
December 24, 2018When 2018 began, there was still plenty of uncertainty surrounding the previously untreated lung cancer market—the holy grail for immuno-oncology drugmakers, thanks to its sheer size. -
As immuno-oncology heads into 2019, one thing is clear: It’s good to be Merck
December 24, 2018When 2018 began, there was still plenty of uncertainty surrounding the previously untreated lung cancer market—the holy grail for immuno-oncology drugmakers, thanks to its sheer size.
Pharma Sources Insight January 2025
